Medicure Inc. (CVE:MPH – Get Free Report)’s stock price passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of C$1.15 and traded as low as C$1.04. Medicure shares last traded at C$1.04, with a volume of 1,000 shares.
Medicure Trading Down 1.9%
The company has a quick ratio of 1.28, a current ratio of 1.04 and a debt-to-equity ratio of 6.34. The company has a market cap of C$10.85 million, a P/E ratio of -1.60 and a beta of 0.49. The firm’s 50 day moving average is C$1.16 and its two-hundred day moving average is C$1.15.
About Medicure
Medicure Inc, a biopharmaceutical company, engages in the research, development, and commercialization of human therapies in the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company is developing Sodium Nitroprusside injection, and Generic ANDA 2 and 3 for acute cardiology; and TARDOCAL, to treat neurological indications.
Featured Articles
- Five stocks we like better than Medicure
- The SK Hynix IPO and 2027’s AI Memory Squeeze
- Meta Platforms Stock Rises as Muse Spark 1.1 AI Model Debuts
- Why Welltower’s Growth Story Might Outrun Its Rich Valuation
- One Short- and One Long-Term ETF for Quantum Computing Bulls
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
